Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets

Key Inclusion Criteria: * Healthy, adult, male or female 19-55 years of age * Continuous non-smoker who has not used nicotine and tobacco-containing products for at least 3 months prior to the first dosing * Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 * Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, or 12-lead safety ECGs at the screening visit, as deemed by the PI or designee * Understands the study procedures in the informed consent form (ICF) and be willing and able to comply with the protocol. Key Exclusion Criteria: * Mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study * Clinically significant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neoplastic myeloproliferative, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine or connective tissue diseases or disorders * History of any gastrointestinal surgery or cholecystectomy that could impact the PK of NX-5948 * History or presence of alcohol or drug abuse within the past 2 years * History or presence of hypersensitivity, angioedema, or idiosyncratic reaction to the study drug(s) or related compounds * History or presence of: * Significant multiple and/or severe allergies, including anaphylactic reaction. * Personal or family history of prolonged QT syndrome or family history of sudden cardiac death. * Evidence of atrial fibrillation, atrial flutter, complete bundle branch block, Wolff Parkinson-White Syndrome, or cardiac pacemaker. * Adrenal insufficiency. * Skin infection. * Female volunteers of childbearing potential * Female volunteer with a positive pregnancy test * Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at the screening visit * Donation of blood or significant blood loss within 56 days prior to the first dosing * Plasma donation within 7 days prior to the first dosing * History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee. * Previous exposure to NX-5948. * Participation in another clinical study within 30 days or within 5 half-lives (if known), prior to the first dosing, whichever is longer. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.